(Q37242253)

19 August 2017

1 reference

title

Thiazolidinediones in type 2 diabetes: a cardiology perspective (English)

1 reference

19 August 2017

0 references

Rodica Pop-Busui

2

0 references

Kim A. Eagle

series ordinal

3

object named as

Kim A Eagle

1 reference

19 August 2017

Ujjaini Khanderia

1

1 reference

PubMed ID

18698014

19 August 2017

language of work or name

English

0 references

publication date

2 September 2008

1 reference

Annals of Pharmacotherapy

19 August 2017

1 reference

19 August 2017

42

1 reference

19 August 2017

10

1 reference

19 August 2017

1466-1474

1 reference

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

19 August 2017

1 reference

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

21 January 2018

1 reference

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

Cardiovascular complications of diabetes: prevention and management

21 January 2018

1 reference

Role of diabetes in congestive heart failure: the Framingham study

21 January 2018

1 reference

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction

21 January 2018

1 reference

Endothelial inflammation in insulin resistance

21 January 2018

1 reference

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease.

21 January 2018

1 reference

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

21 January 2018

1 reference

Advanced glycation end products, oxidant stress and vascular lesions

21 January 2018

1 reference

The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis

21 January 2018

1 reference

Glycemic control and heart failure among adult patients with diabetes

21 January 2018

1 reference

The association between glucose abnormalities and heart failure in the population-based Reykjavik study

21 January 2018

1 reference

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

21 January 2018

1 reference

21 January 2018

1 reference

Endothelial function, inflammation, and prognosis in cardiovascular disease

21 January 2018

1 reference

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

21 January 2018

1 reference

Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone

21 January 2018

1 reference

Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone

21 January 2018

1 reference

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

21 January 2018

1 reference

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

The PROactive study: some answers, many questions

21 January 2018

1 reference

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

Approach to the management of diabetic patients with heart failure: role of thiazolidinediones

21 January 2018

1 reference

Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

21 January 2018

1 reference

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

21 January 2018

1 reference

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study

21 January 2018

1 reference

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

21 January 2018

1 reference

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications

21 January 2018

1 reference

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes

21 January 2018

1 reference

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1K666

1 reference

19 August 2017

1 reference

PubMed ID

18698014